We are live on ! Find out more
STRO icon

Sutro Biopharma

87 hedge funds and large institutions have $46.4M invested in Sutro Biopharma in 2025 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 33 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more capital invested

Capital invested by funds: $39.6M → $46.4M (+$6.72M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

0.28% less ownership

Funds ownership: 6.58%6.3% (-0.28%)

12% less funds holding

Funds holding: 9987 (-12)

39% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 33

55% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 22

Holders
87
Holders Change
-12
Holders Change %
-12.12%
% of All Funds
1.14%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
10
Increased
20
Reduced
33
Closed
22
Calls
$5K
Puts
Net Calls
+$5K
Net Calls Change
-$36K

STRO Hedge Fund Activity: Q3 2025 in Review

87 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q3 2025, worth a combined $46.4M — up 17% from $39.6M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of STRO and 10 opened new positions — a net loss of 12 holders — while 33 trimmed existing stakes and 20 added.

The largest buyer was Renaissance Technologies, adding an estimated $435K. The largest seller was AQR Capital Management, cutting an estimated $560K.

  • 87 institutional investors held Sutro Biopharma (STRO) as of Q3 2025, down from 99 in Q2 2025.
  • Funds reported $46.4M of Sutro Biopharma stock for Q3 2025, up 17% quarter-over-quarter.
  • 10 funds opened new Sutro Biopharma positions in Q3 2025 and 22 closed out, a net change of -12 holders.
  • The largest Sutro Biopharma buyer in Q3 2025 was Renaissance Technologies, an estimated $435K added.
  • The largest Sutro Biopharma seller in Q3 2025 was AQR Capital Management, an estimated $560K sold.

Based on aggregated 13F filings for Q3 2025.